Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights
15 nov. 2022 08h00 HE
|
Vyant Bio, Inc.
Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered...